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Cholesterol is known to be a major risk factor for coronary heart disease (CHD). Current treatments for elevated blood cholesterol
include dietary management, regular exercise, and drug therapy with ﬁbrates, bile acid sequestrants, and statins. Such therapies, how-
ever, areoftensuboptimalandcarryariskforserioussideeﬀects.Thisstudyshowsthatmicroencapsulated Lactobacillusplantarum80
(pCBH1) cells can eﬃciently break down and remove bile acids, and establishes a basis for their use in lowering blood serum choles-
terol. Results show that microencapsulated LP80 (pCBH1) is able to eﬀectively break down the conjugated bile acids glycodeoxycholic
acid (GDCA) and taurodeoxycholic acid (TDCA) with bile salt hydrolase (BSH) activities of 0.19 and 0.08µmol DCA/mg CDW/h
respectively. This article also summarizes the physiological interrelationship between bile acids and cholesterol and predicts the oral
doses of microencapsulated Lactobacillus plantarum 80 (pCBH1) cells required for lowering cholesterol.
INTRODUCTION
Coronary heart disease (CHD) is the main cause
of death in Canada, the US, and many other countries
around the world [1, 2]. The World Health Organization
(WHO) predicts that by the year 2020, up to 40% of all
deaths will be related to cardiovascular diseases or disease
of the heart [3]. Although cholesterol is an important ba-
sic building block for body tissues, elevated blood choles-
terol is a well known major risk factor for CHD [4, 5]. Re-
cent modalities for lowering blood cholesterol levels in-
volve dietary management, behavior modiﬁcation, regu-
lar exercise, and drug therapy [6, 7, 8, 9]. Pharmacologic
agents such as ﬁbrates, nicotinic acid, bile acid seques-
trants, and statins are also available for the treatment of
high cholesterol. Although these drugs eﬀectively reduce
cholesterol levels, they are expensive and are known to
have severe side eﬀects [10, 11, 12].
Bile salts are the water-soluble end products of choles-
terol, and are synthesized in the liver. During normal en-
terohepatic circulation (EHC), the average bile salt pool
of 4.0g is secreted into the duodenum twice during each
meal,orana v erageof6–8timesperda yforthepurposeof
forming mixed micelles with the products of lipid diges-
tion [13, 14]. During intestinal transit, 90%–95% of se-
cretedbilesaltsareabsorbedintheterminalileumandare
returned to the liver via the portal vein [15]. The bile salt
pool is replenished by hepatic synthesis of new bile from
serum cholesterol. It has been shown that upon surgi-
cal, pharmacological, or pathological interruption of the
EHC, bile salt synthesis is increased up to 15-fold, lead-
ing to an increased demand for cholesterol in the liver
[13, 16].
Bile acid sequestrants (BAS) are a type of cholesterol-
lowering therapy that interrupt the EHC and cause lower-
ing of blood serum cholesterol through de novo synthesis
of bile acids in the liver. BAS bind bile acids in the intes-
tine and form insoluble complexes that are excreted in the
feces.IthasbeenshownthatBASalonecanreducecholes-
terol concentrations by 10% to 30% [17, 18]. However,
the common BAS cholestyramine resin (Locholest, Ques-
tran), Colesevelam (WelChol), and Colestipol (Colestid)
are known to exhibit major adverse eﬀects [19].
Certain strains of bacteria act directly on bile acids
in the gastrointestinal (GI) tract and are beneﬁcial in
reducing serum cholesterol levels [16, 20, 21]. Control
of cholesterol through oral live bacterial cell therapy is
based on the demonstration that naturally occurring bac-
teria such as Lactobacillus acidophilus, Lactobacillus bul-
garicus, and Lactobacillus reuteri can signiﬁcantly lower
serum cholesterol levels due to BSH activities [16, 20, 21].
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amount of highly BSH active Lactobacillus cells, in the
form of yogurt, might lead to a signiﬁcant reduction of
cholesterol [16]. It has also been reported that the oral
administration of this and other free bacteria can reduce
serum cholesterol levels by 22% to 33% [16, 21]. While
this was very promising, several limiting factors to the
oral administration of free bacteria have been identiﬁed.
For example, of those free bacteria ingested only 1% sur-
vive GI transit limiting the overall therapeutic eﬀect [16].
Also, oral administration of live bacterial cells can cause a
hostimmuneresponseandcanberetainedintheintestine
replacing the natural intestinal ﬂora [21, 22]. Thus, con-
cerns of safety and practicality have prevented the regular
use of this promising therapy in clinical practice.
Artiﬁcial cell microencapsulation is a technique used
to encapsulate biologically active materials in specialized
ultra-thin semipermeable polymer membranes [23]. The
polymer membrane protects encapsulated materials from
harsh external environments, while at the same time al-
lowing for the metabolism of selected solutes capable of
passing into and out of the microcapsule. In this man-
ner, the enclosed material can be retained inside and be
separated from the external environment, making mi-
croencapsulation particularly useful for biomedical and
clinical applications [24, 25, 26, 27, 28]. In the present
study we examine the potential of artiﬁcial cell microen-
capsulated genetically engineered Lactobacillus plantarum
80 (pCBH1) cells for bile acids deconjugation to lower
cholesterol.
MATERIALS AND METHODS
Mediaandchemicals
The sodium salts of glycocholic acid (GCA), tau-
rodeoxycholic (TDCA), glycodeoxycholic acid (GDCA),
and deoxycholic acid (DCA) were supplied by SIGMA
(St Louis, Mo). De Man-Rogosa-Sharpe (MRS) broth was
obtained from Difco (Sparks, Md). The water was pu-
riﬁed with an EASYpure Reverse Osmosis System and
a NANOpure Diamond Life Science (UV/UF) ultrapure
water system from Barnstead/Thermoline (Dubuque,
Iowa). Methanol was HPLC-gradient from Fisher Scien-
tiﬁc(FairLawn,NJ).Allotherchemicalswereofanalytical
grade.
Bacterialstrainsandgrowthconditions
The bacterial strain used in this study is the bile
salt hydrolytic (BSH) isogenic Lactobacillus plantarum 80
(pCBH1) strain. Overproduction of the BSH enzyme in
LP80 (pCBH1) was obtained as described by Christiaens
et al [29]. The BSH overproducing LP80 (pCBH1) strain
carries the multicopy plasmid pCBH1 carrying the LP80
(pCBH1) chromosomal bsh gene and an erythromycin-
resistance gene.
The Lactobacillus strains were grown in MRS broth at
37◦C in a Sanyo MIR-162 bench top incubator. The MRS
broth was supplemented with 100µg/mL erythromycin
from FisherBiotech (Fair Lawn, NJ) to select bacteria car-
rying the multicopy plasmid pCBH1.
MicroencapsulationofLactobacillus
plantarum80(pCBH1)
50ml of 1.5% low-viscosity alginate (Kelco, Chicago,
Ill) solution was prepared and ﬁltered through a 0.22µm
Sterivex-GS ﬁlter (Millipore, Bedford, Mass) into a sterile
60mL syringe. LP80 (pCBH1) was grown at 37◦Ci nM R S
broth and prepared as a concentrated microorganism
suspension by resuspension of microorganism in 10mL
of sterilized physiologic solution. The 10mL concen-
trated microorganism suspension was added to the 50ml
low-viscosity alginate solution and mixed well. The algi-
nate/microorganism mixture was immobilized through a
300µm nozzle into a ﬁltered solution of CaCl2 with an In-
otech Encapsulator IER-20 (Inotech Biosystems Interna-
tional, Rockville, Md). The immobilized LP80 (pCBH1)
alginate beads were washed in sterilized physiological so-
lution (8.5g/L NaCl), placed in a 1% solution of poly-L-
lysine from Sigma (St Louis, Mo) for 10 minutes, washed
in physiological solution, placed in 1% solution of low-
viscosity alginate for 10 minutes, and washed in physi-
ological solution a ﬁnal time. This procedure was per-
formed in a Microzone Biological Containment Hood
(Microzone Corporation ON, Canada) to assure steril-
ity. The microencapsulated LP80 (pCBH1) (Figure 1)w a s
stored in 1.0L minimal solution (10% MRS and 90%
physiologic solution) at 4◦C to mimic presale product
storage.
BSHactivityofLactobacillusplantarum80
(pCBH1)microcapsules
To investigate the BSH activity of the microencapsu-
lated BSH overproducing LP80 (pCBH1), batch experi-
ments were performed. Five grams of microencapsulated
LP80 (pCBH1) was added to fresh MRS broth to which
10.0mM GDCA and 5.0mM TDCA were added. Samples
were taken at regular time intervals during the 12-hours
incubation to determine the bile salt concentration in the
reaction vessels. The experiment was performed in trip-
licate. (HPLC calibration curves for GDCA and TDCA
measurements were used; see Supplement 1.)
Bilesalthydrolaseassay
A modiﬁcation of the HPLC procedure described by
Scalia[30]wasusedtodetermineBSHactivity[31].Anal-
yses were performed on a reversed-phase C-18 column:
LiChrosorb RP-18, 5µm, 250 × 4.6mmfromHiChrom
(Novato, Calif). The HPLC system was made up of two
ProStar 210/215 solvent delivery modules, and a ProStar
320 UV/Vis Detector, and a ProStar 410 AutoSampler,
and Star LC Workstation Version 6.0 software was used.
The solvents used were HPLC-grade methanol (solvent
A), and solvent B, which was acetate buﬀer prepared
daily with 0.5M sodium acetate, adjusted to pH 4.3
with o-phosphoric acid, and ﬁltered through a 0.22-µm2004:1 (2004) Microencapsulated Cells for Bile Acid Deconjugation and Cholesterol 63
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Figure 1. (a) Photomicrograph of Lactobacillus plantarum 80 (pCBH1) microcapsules at 77× magniﬁcation and (b) at 112× magni-
ﬁcation.
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Supplement 1. HPLC calibration curves for GDCA and TDCA measurements. (a) GDCA coeﬀ.d e t .( r 2): 0.987599. (b) TDCA coeﬀ.
det. (r2): 0.991610.
ﬁlter (Whatman, England). An isocratic elution of 70%
solvent A and 30% solvent B was used at a ﬂow rate of
1.0mL/minute at room temperature. An injection loop
of 20µL was used, and the detection occurred at 205nm
within 25minutes after injection of the bile salt extract.
Quarter-mL samples to be analyzed were acidiﬁed by
the addition of 2.5µL of 6 N HCl to stop any further en-
zymatic activity. A modiﬁcation of the extraction proce-
dure described by Cantafora was used [16, 31, 32]. From
the 0.25-mL sample, bile salts were extracted using a solu-
tion of methanol (1:1; v:v). GCA was added as an internal
standard at 4.0mM. The samples were mixed vigorously
for 10 minutes and centrifuged at 1000g for 15 minutes.
The supernatant was then ﬁltered through a 0.22µLs y -
ringe driven HPLC ﬁlter (Millipore, Japan) and the sam-
ples were analyzed directly after ﬁltration.64 Mitchell Lawrence Jones et al 2004:1 (2004)
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Figure 2. (a) Overlaid HPLC chromatograms of bile acids over time (0, 1, 2, 3, 4, 5, and 6 hours). Decreasing peak areas of TDCA and
GDCAindicate BSH activity of Lactobacillus plantarum80 (pCBH1)microcapsules. (b)BSHactivity and GDCAandTDCAdepleting
eﬃciency of Lactobacillus plantarum 80 (pCBH1) microcapsules in in vitro experiment. The concentration of GDCA and TDCA bile
acids are shown over time.
RESULTS
Preparationofartiﬁcialcellmicrocapsulescontaining
geneticallyengineeredLactobacillusplantarum80
(pCBH1)cellsanddeterminationofbileacidsbyHPLC
Artiﬁcial cell microcapsules containing genetically
engineered Lactobacillus plantarum 80 (pCBH1) cells
(Figure 1) were prepared using the methods described
above and were stored at 4◦C for use in experiments.
Sterile conditions and procedures were strictly adhered to
during the process of microencapsulation. For all exper-
iments, alginate was used as it is a commonly available
immobilization product which is derived from seaweed
and is known to be nontoxic [33]. Alginate provides the
necessary medium for preparation of an APA membrane,
which is well characterized and known for cell environ-
mental isolation including immunoisolation [34].
Known quantities of GDCA and TDCA were added to
MRS broth and 0.25-mL samples were analyzed using the
modiﬁed HPLC bile salt hydrolase assay (Figure 2). Us-
ing 4.0mM GCA internal standard, correlation of deter-
minant factors (R2) of 0.987599 for GDCA and 0.991610
for TDCA were obtained and used in all experiments.
BSHactivityofLactobacillusplantarum80
(pCBH1)microcapsules
The BSH activity of the microencapsulated LP80
(pCBH1) cells was determined to evaluate the poten-
tial for depleting high concentrations of bile acids. Five
grams of microencapsulated LP80 (pCBH1) was incu-
bated in MRS broth supplemented with 10.0mM GDCA
and 5.0mM TDCA and sample was analyzed. The con-
centration of bile acids was monitored by analyzing me-
dia samples at regular intervals over 12 hours. Figure 2a
Table 1. Bile salt hydrolase (BSH) activity (µmol DCA/mg
CDW/h) of microencapsulated Lactobacillus plantarum 80
(pCBH1) towards glyco- and tauro-bile acids.
Strain
BSH activity
(µmol DCA/mg CDW/h)
GDCA TDCA DCA
Microencapsulated
LP80 (pCBH1) 0.19 0.08 0.27
shows superimposed HPLC chromatograms of bile acids
in reaction media at 0 hour, 1 hour, 2 hours, 3 hours,
4 hours, 5 hours, and 6 hours. Decreasing peak areas of
TDCAandGDCAbileacidsindicateBSHactivityofLP80
(pCBH1) microcapsules. The BSH activity of microen-
capsulated LP80 (pCBH1) towards glyco- and tauro-bile
acids was also analyzed (Table 1).
The BSH activity of 0.26g CDW of microencapsu-
lated LP80 (pCBH1) was calculated based on the deple-
tion of 0.2mmol of GDCA in a 4-hour period, and the
BSH activity towards TDCA was based on the breakdown
of 0.1mmol of TDCA in a 5-hour period. Also, this cal-
culation was based on the in vitro depletion of bile acids
with 0.26g CDW LP80 (pCBH1) in 5.0g alginate micro-
capsules in a complex mixture of the bile acids. Figure 2b
shows the BSH activity of LP80 (pCBH1) microcapsules
in the in vitro bile acid experiment over a 12 hours pe-
riod. The concentration of GDCA and TDCA bile acids
were found to decrease over time.
Figure 2b shows that the BSH activity of LP80
(pCBH1) began immediately and depleted GDCA at a
greater initial rate. While TDCA also began to breakdown
immediately, it did so at a slower rate than GDCA. The2004:1 (2004) Microencapsulated Cells for Bile Acid Deconjugation and Cholesterol 65
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Figure 3. (a) Overlaid HPLC chromatograms of samples (0, 1, 2, 3, 4, 5, and 6 hours) from experiment in which microencapsulated
LP80 (pCBH1) was used to deconjugate 10mM GDCA and 5mM TCDA. (b) Overlaid HPCL chromatograms of samples (0, 1, 2, 3,
4, 5, and 6 hours) from experiment in which immobilized LP80 (pCBH1) was used to deconjugate 10mM GDCA and 5mM TCDA.
removal of GDCA, however, experienced concentration
eﬀects as it was depleted early and thus the breakdown of
GDCA slowed as the experiment progressed and the BSH
activity towards TDCA increased.
To investigate the fate of the products of deconjuga-
tion, experiment was performed using a calibration of
increasing concentrations of TDCA, GDCA, and DCA.
Figure 3a shows superimposed HPLC chromatograms of
samples at 0 hour, 1 hour, 2 hours, 3 hours, 4 hours,
5 hours, and 6 hours. Decreasing peak areas of TDCA
and GDCA bile acids indicate BSH activity of microen-
capsulated LP80 (pCBH1). We compared these results to
earlier studies using immobilized beads containing LP80
(pCBH1) (Figure 3b). Decreasing peak areas of TDCA
and GDCA bile acids indicate BSH activity of alginate
beads containing immobilized LP80 (pCBH1). The peak
detected just before the measured TDCA peak was dimin-
ished totally within 4 hours and corresponds to the cal-
ibration peak of DCA. The absence of a corresponding
peak in the encapsulation results shows the clear advan-
tage of using encapsulated cells.
DISCUSSION
Earlier studies have shown that free LP80 (pCBH1)
cells can be use to break down bile acids in vitro [16]. We
intended to prove the eﬃcacy of the microencapsulated
bacteriaatbreakingdowntauro-andglyco-bileacids,and
hence establish a basis for their use in lowering blood
serum cholesterol when administered orally. Results ob-
tained in this study clearly show that microencapsulated
LP80 (pCBH1) was able to eﬀectively break down phys-
iologically relevant concentrations of bile acids in vitro.
The BSH activity results show that 0.26g CDW of mi-
croencapsulatedLP80(pCBH1)canbreakdown0.2mmol
of GDCA in a 4-hour period and 0.1mmol of TDCA in
a 5-hour period against an average hepatic bile salt se-
cretion of 2.0mmol/4h [13, 35]. Thus, an oral adminis-
tration of microcapsules, containing 1.85g CDW of LP80
(pCBH1), would have the capacity to completely break-
down the total bile salt secretion in the average human
during a 4-hour intestinal transit period. However, break-
ingdownallsecretedbilesaltsmaynotbethegoalofther-
apy with microencapsulated LP80 (pCBH1), as some bile
acids are required for intestinal absorption of fat through
formation of mixed micelles. Even so, enzymatic break-
down of the bile salt pool in this way would have an im-
pact on serum cholesterol due to the deconjugation of
tauro- and glyco-bile acids and their resulting de-novo
synthesis, from serum cholesterol, in the liver (Figure 4a).
In the average human, conjugated bile salts are pro-
duced from cholesterol and taruine or glycine at a rate
of 0.02mmol/h in the liver [37]. During normal EHC,
the average bile salt pool of 4.0g is secreted into the
duodenum twice during each meal, or an average of 6–
8t i m e sp e rd a y[ 13, 14] for lipid digestion (Figure 4b).
Daily bile acid secretions approach 20–30g [13, 14]o r
20–60mmol [38] sustaining an intestinal bile salt concen-
tration of 5–20mM [15]. During intestinal transit, 90%–
95% of secreted bile salts are reabsorbed in the terminal
ileum and are returned to the liver via the portal vein
[15]( Figure 4b). About 75% of the bile acid secretion is
reabsorbed in the conjugated form in an active sodium-
dependent way [15]. The remaining 25% is hydrolyzed
during intestinal transit and only 15% is reabsorbed
in a passive way [15]( Figure 4b). Thus, about 60% of66 Mitchell Lawrence Jones et al 2004:1 (2004)
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Figure 4. (a) Hydrolysis of conjugated bile salts by the bile salt hydrolase (BSH) enzyme overproduced by genetically engineered
Lactobacillus plantarum 80 (pCBH1) [36]. R indicates the amino acid glycine or taurine. RDCA: glyco- or tauro-deoxycholic acid,
DCA: deoxycholic acid. (b) Enterohepatic circulation of bile (EHC) [13, 14, 15, 35, 37].
deconjugated bile acids are reabsorbed. Thus, one mmol
of deconjugated bile salt, formed through breakdown by
microencapsulated LP80 (pCBH1), is responsible for a
0.4-mmol faecal excretion [13]. It is consequently re-
quired for this amount to be replaced by newly synthe-
sized bile salts from blood serum cholesterol. In this way,
interruption of the EHC can result in an increased bile
acid biosynthesis of up to 15-fold, from 0.02mmol/h to
0.3mmol/h [37]. One may calculate the eﬀects that dif-
ferent dosages of microencapsulated LP80 (pCBH1) can
have on blood serum cholesterol levels through interrup-
tion of the EHC in this way (Figure 5).
Microencapsulated LP80 (pCBH1) was able to decon-
jugate GDCA and TDCA completely within 4 hours and 5
hours respectively (Figure 3a). Earlier, immobilized LP80
(pCBH1) was able to eﬀectively break down GDCA and
TDCA bile acids within 5 hours and 6 hours respectively
(Figure 3b). However, the deconjugation product, deoxy-
cholicacid(DCA),wasdetected(Figure 3b).Thissuggests
that unlike immobilized cells, microencapsulated cells di-
minish the bioavailability of BSH-deconjugated bile acids
totally (Figure 4). This ﬁnding may improve the thera-
peutic properties of microencapsulated LP80 (pCBH1)
in several ways. For example, it addresses concerns over
the production of large amounts of deconjugated bile
salts and their association with an increased risk of de-
veloping colon cancer. Also, if bile salts are actually be-
ing deconjugated, precipitated, and then bound within2004:1 (2004) Microencapsulated Cells for Bile Acid Deconjugation and Cholesterol 67
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Figure 5. Predicted removal of cholesterol from blood serum
in humans. The calculation is based on dose data from in
vitro experimental results and physiologic data from the lit-
erature. The calculation assumes an average bile salt synthesis
of 0.02mmol/h, a daily bile salt secretion of 40mmol (normal
range:20–60mmol)[38],andthatwithinterruptionoftheEHC
bile acid synthesis increases up to 15-fold [15, 37].
the microcapsule, microencapsulated LP80 (pCBH1) may
be capable of removing all bile acid from the GI lumen.
This eﬀect contrasts previous results, using free bacteria,
where the authors predicted only an improved clearance
(from 95% for conjugated to 60% for deconjugated) of
bile acids from the EHC and not total clearance [16].
Further, elevated intraluminal concentrations of decon-
jugated bile acids in the colon, normally resulting in an
increased secretion of electrolytes and water and caus-
ing diarrhea [37], would cease to present diﬃculty, as
the deconjugated bile acids would be entirely precipitated
and bound within the microcapsules and excreted in the
stool.
It is now well known that statins increase the risk of
myopathy in patients receiving large dosages and in pa-
tients with renal or hepatic impairment, serious infec-
tions, hypothyroidism, or advanced age [39]. In such pa-
tients, and in patients with an inadequate LDL lowering
response to statins, it is widely accepted that combination
therapy with a bile acid sequestrant or niacin should be
considered [39, 40, 41, 42]. We submit that microencap-
sulated LP80 (pCBH1) may also prove to be an excellent
choice of cholesterol-lowering agents for use in combina-
tion therapy with statins and other lipid-lowering thera-
pies.
While this in vitro study shows the potential for
cholesteroltherapywithLP80(pCBH1),therearenumber
ofadditionalfactorsthatmustbetakenintoconsideration
in proceeding with in-vivo experimentation. Important
considerations may include dosage, frequency and timing
of therapeutic administration, composition of microcap-
sule membrane, and potential side eﬀects of by-products.
There is reason, however, to believe that the deconjugate
by-products are made less bioavailable, as shown by the
results in Figure 3. While these factors present challenges
in implementing this approach, we believe the potential
risks to be very low.
This study has shown that microcapsules contain-
ing LP80 (pCBH1) have several advantages to the free
or immobilized bacteria. Microencapsulation renders
the potentially harmful products of BSH deconjugation,
namely DCA, less bioavailable while at the same time
avoid the problems with oral administration of free bac-
terial cells. However, further research is required to sub-
stantiate these results, in particular in-vivo aﬃrmation of
the cholesterol-lowering capacity of LP80 (pCBH1) is re-
quired before complete potential of this research can be
comprehended.
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